Article Search

The cohort included 229 467 patients; 86 422 (37.7%) received glucagon-like peptide-1 receptor agonist (GLP-1RA), while 143 045 (62.3%) received diet or exercise consultation. With a median follow-up of 2 years (interquartile range 1-2 years), the propensity score matching analysis showed a significantly lower incidence of any Obesity Associated Cancers among GLP-1RA users (hazard ratio 0.59, 95% confidence interval 0.53-0.67). Secondary analyses showed that in all subgroups, except for black race, GLP-1RA use was associated with a lower cumulative incidence of OACs. GLP-1 will be studied more often in cancer patients, some practices, already have GLP-1 clinic as part of their cancer care.

More evidence that being physically active may enhance QOL and survival. Prospective studies are needed to show that physical activity intervention actually achieves such degree of improvements, and that the non-exercise population is not self-selected due to comorbidities.